Compare · NVO vs TELO
NVO vs TELO
Side-by-side comparison of Novo Nordisk A/S (NVO) and Telomir Pharmaceuticals Inc. (TELO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TELO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.92B, about 2260.9x TELO ($86.7M).
- Over the past year, NVO is down 42.5% and TELO is down 35.3% - TELO leads by 7.2 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 1 for TELO).
- Company
- Novo Nordisk A/S
- Telomir Pharmaceuticals Inc.
- Price
- $44.30+0.95%
- $1.29+1.57%
- Market cap
- $195.92B
- $86.7M
- 1M return
- -3.34%
- +4.88%
- 1Y return
- -42.52%
- -35.34%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 4
- 4
- Recent ratings
- 25
- 1
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest TELO
- Telomir Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
- SEC Form 3 filed by new insider Mushak Andriy
- Telomir Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form 4 filed by CEO and Chairman Aminov Erez
- SEC Form 4 filed by Director Whalen Matthew Pratt
- SEC Form 4 filed by Director Macpherson Edward Clouston
- SEC Form 4 filed by Director Del Giudice Matthew Paul
- Telomir Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease